Genome sequencing identifies a basis for everolimus sensitivity - Wikidata - awgldk - TriplyDB

Genome sequencing identifies a basis for everolimus sensitivity

Genome sequencing identifies a basis for everolimus sensitivity

http://www.wikidata.org/entity/Q24631915

about

Prognostic Genetic Signatures in Upper Tract Urothelial Carcinoma Muscle-invasive urothelial bladder cancer: an update on systemic therapy Translating cancer genomes and transcriptomes for precision oncology Next-Generation Sequencing Approaches in Cancer: Where Have They Brought Us and Where Will They Take Us?Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development Toward rapamycin analog (rapalog)-based precision cancer therapy Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends Targeted therapy in advanced bladder cancer: what have we learned?Multimodal management of muscle-invasive bladder cancer Advances in the Molecular Analysis of Soft Tissue Tumors and Clinical Implications Prospects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderly Cytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough?Clinical tumor sequencing: opportunities and challenges for precision cancer medicine CIViC database Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.Response and acquired resistance to everolimus in anaplastic thyroid cancer Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls Improving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assays Bladder cancer in the elderly patient: challenges and solutions Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise Comprehensive molecular characterization of urothelial bladder carcinoma PI3K and cancer: lessons, challenges and opportunities Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.Informing materials: drugs as tools for exploring cancer mechanisms and pathways.Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47)Assessing the clinical utility of cancer genomic and proteomic data across tumor types.Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy Using high-throughput sequencing transcriptome data for INDEL detection: challenges for cancer drug discovery.OncDRS: An integrative clinical and genomic data platform for enabling translational research and precision medicine A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response A Phase I Trial of Temsirolimus and Pemetrexed in Patients with Advanced Non-Small Cell Lung Cancer.Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel

P2860

489d576260c5927252d1c78b7f16ddbe4c986036 f244575c0829d7d8db3229383cf47c6255a6b2db

P248

Q26772220-48D9CD56-EDD0-4C43-BCA2-CDCDF344527C Q26775780-A4538B80-41B4-458E-A5BB-43340D1925A7 Q26777081-0C27FFC6-43E7-4B84-A8C1-7CE83EF43B96 Q26781271-0F127DFB-BE81-42C0-B6D2-2C769297A0F3 Q26783932-F1D2CEEC-EC51-4102-829B-4C22D0A12674 Q26795606-F898D281-6ABE-4AAF-A890-7D245C3E5D82 Q26830194-31AE3501-1440-4239-9C92-D39CE4868AA3 Q27009469-A557549B-9459-4DE9-9A01-381ADA65B66E Q27011624-EB83AB25-58A2-4180-B7D1-FF1696FF9252 Q27021848-C074A8CB-64D0-430D-9E55-8D04B92E6B7F Q27025344-7908A595-E93A-4C05-B3E4-A4067DD3D841 Q27026717-B5CADE68-2761-4C26-9D1C-FF9B8EB6E23D Q27027942-6989B6FB-2D2F-4BAC-BE90-B2B40A70BF4D Q27612411-7DEB6B5F-6447-4B31-9B8A-39728A5206EF Q27852242-2D35904D-2496-49AD-8D02-BE5B9AEC4CD4 Q27852873-90C96715-9CAD-4C1A-AD0F-1C5D3C9AE737 Q27852894-B10BAAB6-21A8-47BC-B5D2-EBBBEB42C559 Q27852954-D489A946-EDA3-41AD-91CE-BDF764749ABA Q27853080-7EC947D8-D674-4F0A-8BE3-08D3DAA6905C Q27853151-6D4D9D54-83E1-42E0-8E96-598295BC9D5A Q27853189-FFB3CBA3-554A-4506-B22F-10A9B6518B2B Q28066709-23D0A8C3-66D3-4B19-B62C-99C7F5E18186 Q28077848-2B57F2DD-443E-4728-817D-670C78E59168 Q28082782-CCA099AB-4AA3-4D9F-9EE7-31683DEDF2B6 Q28084715-F61EC551-DF6B-409F-824D-7451A9BC59E2 Q28088334-0B65B4A2-FC20-4D52-B54F-EF6846914F31 Q28306864-690A95BA-6AA4-4801-A606-FB204FEABA86 Q30080017-C9EF44E7-4FBD-4201-BD45-1F842EB1F63F Q30240816-09AE31A6-4665-4747-849C-9EEA37E97462 Q30402161-3A8FE522-B0CC-49D4-9516-57D651C5CA59 Q30412106-97B56CEC-D8FB-446E-A6D3-B193B5175250 Q30487077-C9149F7A-B9FC-4EA9-80EF-446C0CDB93B9 Q30563774-1ADE967A-0A50-4FB4-9145-1A7AF21402FF Q31038214-0EA40F8B-B259-42E6-88EF-E90CB3D6E7F5 Q31070571-4F395299-F235-4E5D-953B-6D7BDE0A148E Q33407185-F71B856D-66CC-47D2-A904-9DEA5FDFFDAD Q33413598-885DA4D3-56BB-4BF9-BF57-30BDA44FD1A3 Q33422744-1EB49056-FDBB-4A30-87AD-C2E2A2AF9B58 Q33429306-85997274-3B81-4C8B-8212-C7BBDA199508 Q33699641-D931A078-9C46-42BB-A26D-908C9639C431

P2860

Genome sequencing identifies a basis for everolimus sensitivity

http://www.wikidata.org/entity/Q24631915

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Genome sequencing identifies a basis for everolimus sensitivity

@ast

Genome sequencing identifies a basis for everolimus sensitivity

@en

Genome sequencing identifies a basis for everolimus sensitivity

@nl

type

label

Genome sequencing identifies a basis for everolimus sensitivity

@ast

Genome sequencing identifies a basis for everolimus sensitivity

@en

Genome sequencing identifies a basis for everolimus sensitivity

@nl

altLabel

Genome Sequencing Identifies a Basis for Everolimus Sensitivity

@en

prefLabel

Genome sequencing identifies a basis for everolimus sensitivity

@ast

Genome sequencing identifies a basis for everolimus sensitivity

@en

Genome sequencing identifies a basis for everolimus sensitivity

@nl

P1433

Q24631915-B58C451D-D98A-494A-9017-9773ED5270C6

P1476

Q24631915-D8712E7C-25B4-4B95-9C81-22F5224EA01A

P2093

Q24631915-02A44D73-BCA8-41A7-8537-C4C4885E100D

Q24631915-07BD351C-8153-4804-AFA5-0138A69558AD

Q24631915-09BEB64F-FBCE-4A11-AC3D-11E59CA6F3D5

Q24631915-104D045C-F244-4BB1-9284-411D3F205635

Q24631915-1AA0DE4C-C23E-49C9-ACC5-52F7F3814A88

Q24631915-1B769540-F43B-44F2-A329-AA59EED06A9D

Q24631915-4255CAB7-BF4C-409E-AA73-851034DB97DF

Q24631915-5B960556-63B4-4504-B6CE-0DCBA75ED27B

Q24631915-696C2674-3BBA-4AFE-8B34-62FDA94FC29F

Q24631915-7DD18B39-7C14-4A69-8B89-F9B8875E3886

P2860

Q24631915-1180F5D4-A4A9-4BFE-8082-71B18002EA9A

Q24631915-25F36704-63ED-4B26-916A-423ED2709766

Q24631915-317E8CBE-47D1-40E5-B41E-C72762EA8768

Q24631915-376EEF79-C650-404B-A64E-73871CB99515

Q24631915-38D0B03A-32B3-49A6-A6AD-C8D801FFF4CE

Q24631915-4A8DC179-5EFE-48B1-B602-C47CE04763E7

Q24631915-4E79C895-1C65-41A7-985A-9BC2F5334FEE

Q24631915-58351979-1654-473B-9C68-D89166E22403

Q24631915-7531717A-72C0-47BF-A581-7849B6C1AFC7

Q24631915-782ACFD1-178D-48DC-BC3F-52B41538649E

P304

Q24631915-7D49A4C5-3916-4163-AFB7-BF6CB37E6D15

P31

Q24631915-DF25A3F8-6691-4C0E-AC1E-A873367B29DD

P3181

Q24631915-DA2717AA-2630-452A-8AA5-F5CB9E42AF9D

P356

Q24631915-B4B3D339-9A15-4EEF-8029-E3751C9DA643

P407

Q24631915-D57A9344-562C-4E34-9EFB-FC7C9F0953CB

P433

Q24631915-F910FD8C-E9B1-47FA-816A-E8EC00D021AE

P478

Q24631915-D3135EE3-4F00-430C-A49B-6245D0C78637

P50

Q24631915-CF957899-A7AC-40FB-BEAD-DF31E5BCD5DB

P577

Q24631915-AB0AE83E-34DA-42FB-8D7B-B17C7F00F79B

P5875

Q24631915-85196B65-75B8-4AF1-AEB7-6A487304315C

P698

Q24631915-99F863C2-B665-410D-BADC-1B78AB2D4A02

P932

Q24631915-DA68451F-8A32-475E-8502-8FDD3C3C1234

P3181

P356

SCIENCE.1226344

P1433

P1476

Genome sequencing identifies a basis for everolimus sensitivity.

@en

P2093

Adriana Heguy

http://www.w3.org/2001/XMLSchema#string

Agnes Viale

http://www.w3.org/2001/XMLSchema#string

Aphrothiti J Hanrahan

http://www.w3.org/2001/XMLSchema#string

Barry S Taylor

http://www.w3.org/2001/XMLSchema#string

Bernard Bochner

http://www.w3.org/2001/XMLSchema#string

David B Solit

http://www.w3.org/2001/XMLSchema#string

Dean F Bajorin

http://www.w3.org/2001/XMLSchema#string

Gopa Iyer

http://www.w3.org/2001/XMLSchema#string

Hikmat Al-Ahmadie

http://www.w3.org/2001/XMLSchema#string

Irina Ostrovnaya

http://www.w3.org/2001/XMLSchema#string

P2860

A map of human genome variation from population-scale sequencing

The genomic complexity of primary human prostate cancer

Initial genome sequencing and analysis of multiple myeloma

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

Integrated genomic analyses of ovarian carcinoma

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

The Sequence Alignment/Map format and SAMtools

A framework for variation discovery and genotyping using next-generation DNA sequencing data

The mutational landscape of head and neck squamous cell carcinoma

Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling.

P304

221

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

835469

http://www.w3.org/2001/XMLSchema#string

P356

10.1126/SCIENCE.1226344

http://www.w3.org/2001/XMLSchema#string

P407

P433

6104

http://www.w3.org/2001/XMLSchema#string

P478

338

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230742266

http://www.w3.org/2001/XMLSchema#string

P698

22923433

http://www.w3.org/2001/XMLSchema#string

P932

3633467

http://www.w3.org/2001/XMLSchema#string